Giri D, Ozen M, Ittmann M
Department of Pathology, Baylor College of Medicine, Houston, Texas 77030, USA.
Am J Pathol. 2001 Dec;159(6):2159-65. doi: 10.1016/S0002-9440(10)63067-2.
Prostate cancer is the most common cancer in American men and the second leading cause of cancer deaths in this group. We have found that interleukin (IL)-6 protein concentrations are increased approximately 18-fold in clinically localized prostate cancers when compared to normal prostate tissue. Normal and neoplastic prostatic epithelial cells in culture, with the exception of LNCaP cells, secrete IL-6. Addition of exogenous IL-6 to primary epithelial cells in culture or the LNCaP prostate cancer cell line leads to phosphorylation of Stat-3 and increases in net cell proliferation. The concentration of IL-6 receptor is increased eightfold in the prostate cancer tissues and is increased in the cancer cells by immunohistochemistry. The increased expression of IL-6 receptor is correlated with increased proliferation of prostate cancer cells in vivo as assessed by Ki67 immunohistochemistry. These findings strongly support the hypothesis that IL-6 acts as a significant autocrine growth factor in vivo for primary, androgen-dependent prostate cancers.
前列腺癌是美国男性中最常见的癌症，也是该群体中癌症死亡的第二大主要原因。我们发现，与正常前列腺组织相比，临床局限性前列腺癌中白细胞介素（IL）-6蛋白浓度增加了约18倍。培养的正常和肿瘤性前列腺上皮细胞，除LNCaP细胞外，均分泌IL-6。向培养的原代上皮细胞或LNCaP前列腺癌细胞系中添加外源性IL-6会导致Stat-3磷酸化并增加细胞净增殖。前列腺癌组织中IL-6受体浓度增加了八倍，通过免疫组织化学检测癌细胞中该受体浓度也增加。通过Ki67免疫组织化学评估，IL-6受体表达增加与体内前列腺癌细胞增殖增加相关。这些发现有力地支持了以下假设：IL-6在体内作为原发性雄激素依赖性前列腺癌的重要自分泌生长因子发挥作用。
